MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Akebia Therapeutics Inc

Suletud

SektorTervishoid

3.86 -0.26

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.83

Max

3.96

Põhinäitajad

By Trading Economics

Sissetulek

29M

6.1M

Müük

11M

57M

Kasumimarginaal

10.66

Töötajad

181

EBITDA

20M

14M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+93.3% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. aug 2025

Turustatistika

By TradingEconomics

Turukapital

431M

1B

Eelmine avamishind

4.12

Eelmine sulgemishind

3.86

Uudiste sentiment

By Acuity

50%

50%

154 / 376 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Akebia Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. juuli 2025, 21:01 UTC

Tulu

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18. juuli 2025, 20:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

18. juuli 2025, 20:50 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

18. juuli 2025, 20:50 UTC

Market Talk
Tulu

Basic Materials Roundup: Market Talk

18. juuli 2025, 20:46 UTC

Tulu

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18. juuli 2025, 20:39 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18. juuli 2025, 20:36 UTC

Tulu

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18. juuli 2025, 20:16 UTC

Omandamised, ülevõtmised, äriostud

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18. juuli 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18. juuli 2025, 20:02 UTC

Market Talk

Gold Higher to Close Out Week -- Market Talk

18. juuli 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18. juuli 2025, 19:06 UTC

Market Talk

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18. juuli 2025, 18:24 UTC

Tulu

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18. juuli 2025, 18:19 UTC

Tulu

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18. juuli 2025, 18:11 UTC

Omandamised, ülevõtmised, äriostud

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18. juuli 2025, 18:11 UTC

Tulu

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18. juuli 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18. juuli 2025, 16:29 UTC

Market Talk

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18. juuli 2025, 16:28 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18. juuli 2025, 16:22 UTC

Tulu

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18. juuli 2025, 16:20 UTC

Market Talk
Tulu

Financial Services Roundup: Market Talk

18. juuli 2025, 16:20 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

18. juuli 2025, 16:20 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

18. juuli 2025, 16:20 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Energy & Utilities Roundup: Market Talk

18. juuli 2025, 16:20 UTC

Market Talk
Tulu

Basic Materials Roundup: Market Talk

18. juuli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18. juuli 2025, 16:04 UTC

Tulu

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18. juuli 2025, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

18. juuli 2025, 15:58 UTC

Market Talk

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18. juuli 2025, 15:47 UTC

Market Talk
Tulu

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Akebia Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

93.3% tõus

12 kuu keskmine prognoos

Keskmine 7.5 USD  93.3%

Kõrge 8 USD

Madal 7 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Akebia Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

2

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

2.345 / N/AToetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

154 / 376 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.